Background: High-dose testosterone treatment is a well-known, though still controversial, therapy in boys with tall stature.
Methods: 161 boys with constitutional tall stature were treated at two different treatment centers (center A 114 patients; center B 47 patients). In center A, boys were treated with 500 mg and in center B with 250 mg testosterone enanthate intramuscularly every 2 weeks. Predicted adult height (PAH) was calculated according to the Bayley/Pinneau method using the Greulich-Pyle method for bone age determination.
Results: At onset of treatment, the patients at the two centers did not differ with respect to chronological age (center A 14.2 ± 1.3 years; center B 13.5 ± 1.1 years), height (center A 187.8 ± 7.3 cm; center B 185.5 ± 5.5 cm), bone age (center A 13.8 ± 0.8 years; center B 13.6 ± 0.7 years), or PAH (center A 205.2 ± 5.2 cm; center B 204.8 ± 5.5 cm). Mean treatment duration was significantly longer in center A than in center B (14.2 ± 4.0 vs. 11.3 ± 2.2 months). At the end of the testosterone treatment, PAH did not differ significantly (center A 197.7 ± 5.3 cm; center B 196.1 ± 4.7 cm). The mean reduction in PAH at the end of treatment was 7.6 ± 5.0 cm (center A) and 8.7 ± 5.6 cm (center B) which is ∼50% of the expected growth at onset of treatment.
Conclusions: A testosterone enanthate dose of 250 mg every 2 weeks was as effective in reducing adult height in boys with tall stature as a dose of 500 mg every 2 weeks.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1159/000332735 | DOI Listing |
Jpn J Clin Oncol
January 2025
Division of Molecular and Cellular Oncology, Miyagi Cancer Center Research Institute, 47-1 Nodayama, Medeshima-Shiode, Natori, Miyagi 981-1293, Japan.
A Japanese woman with Li-Fraumeni syndrome in her 40s underwent comprehensive genetic profiling accompanied by germline data using the Oncoguide NCC Oncopanel, but no germline pathogenic variants in the tumor suppressor gene TP53 were detected. However, careful examination of additional data in the report suggested the presence of a large TP53 deletion. Custom targeting next-generation sequencing and nanopore sequencing revealed a 3.
View Article and Find Full Text PDFInfect Dis (Lond)
January 2025
Department of Epidemiology and Biostatistics, College of Public Health, University of Georgia, Athens, GA, USA.
Background: Whether a detected virus or bacteria is a pathogen that may require treatment, or is merely a commensal 'passenger', remains confusing for many infections. This confusion is likely to increase with the wider use of multi-pathogen PCR.
Objectives: To propose a new statistical procedure to analyse and present data from case-control studies clarifying the probability of causality.
Endocrine
January 2025
Centro di Ricerca e Innovazione sulle Patologie Surrenaliche, AOU Careggi, Florence, Italy.
Purpose: To compare functional deficits associated to surgery with those caused by the growth of the head and neck paragangliomas (HNPGLs).
Methods: 72 patients with HNPGLs were included. Patients were divided in group A (49 patients undergoing surgery) and group B (23 patients following a wait and see approach).
Tech Coloproctol
January 2025
Ellen Leifer Shulman and Steven Shulman Digestive Disease Center, Cleveland Clinic Florida, 2950 Cleveland Clinic Blvd, Weston, FL, USA.
Introduction: Chatbots have been increasingly used as a source of patient education. This study aimed to compare the answers of ChatGPT-4 and Google Gemini to common questions on benign anal conditions in terms of appropriateness, comprehensiveness, and language level.
Methods: Each chatbot was asked a set of 30 questions on hemorrhoidal disease, anal fissures, and anal fistulas.
Calcif Tissue Int
January 2025
Endocrinology Department, School of Medicine, Pontificia Universidad Católica de Chile, Av. Diagonal Paraguay 262, Cuarto Piso, Santiago, Chile.
X-linked hypophosphatemia (XLH) is a rare metabolic disorder characterized by elevated FGF23 and chronic hypophosphatemia, leading to impaired skeletal mineralization and enthesopathies that are associated with pain, stiffness, and diminished quality of life. The natural history of enthesopathies in XLH remains poorly defined, partly due to absence of a sensitive quantitative tool for assessment and monitoring. This study investigates the utility of 18F-NaF PET/CT scans in characterizing enthesopathies in XLH subjects.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!